"Medical Speed Reading Society" WHO suspends hydroxychloroquine test Sanofi sells recycled shares

Changchun Gaoxin plans to spin off its subsidiary, Bourke Bio, to cotronboard listing; Sanofi to sell recycled shares; WHO suspends clinical trials of hydroxychloroquine for the treatment of new coronary pneumonia; the first domestic BTK inhibitor, Zebutini, is about to be approved for listing; and the ipo application for Paampley is accepted ..The National Health and Health Commission and other three departments issued the "Public Health Prevention and Control Capacity Building Program" and issued the provinces, autonomous regions, municipalities directly under the Central Government and planned single-listed cities, Xinjiang Production and Construction Corps Development and Reform Commission, Health and Health Commission, The Chinese Medicine Bureau, requiring the relevant departments to comply with the implementationIt mentioned that to ensure that medical institutions reserve seamount s(a) medical masks, isolation clothing, eye masks and other protective supplies, generally not less than 10 days of use(National Health and Health Commission, etc.) before the, the Drug Review Center of the State Drug Administration issued a notice on the gradual resumption of on-site service by the Drug Review Center of the State Drug AdministrationPersonnel who do not comply with the relevant policies related to the prevention and control of the epidemic in Beijing, please do not conduct business on site(CDE)25, Guangdong, Yunnan, Guangxi, Chongqing, Hunan, Jiangxi, six provinces (municipalities, autonomous regions) drug trading and collection platform respectively announced the "new coronavirus detection reagents alliance regional centralized procurement results." Three groups of 11 products, 10 enterprises selected, Mike Bio in the new coronavirus nucleic acid testing kit and the new coronavirus IgM/IgG antibody testing kit two groups were selected(Pharmaceutical Rubik's Cube)25, Zhejiang Province Pharmaceutical Procurement Center in accordance with the Zhejiang Provincial Medical Security Bureau, "Zhejiang Province Public Medical Institutions part of the medical supplies band procurement work program (draft for comments)," formulated the "Zhejiang Province public medical institutions part of the medical supplies band purchase document (draft for comments)." Opinion draft published the crown pulse intervention drug stent, coronary blood intervention balloon, orthopaedic hip medical supplies procurement program, this procurement cycle is 2 years(Zhejiang Pharmaceutical Procurement Center)Changchun Gaoxin announced on the evening of the 25th, Changchun Gaoxin intends to spin off its subsidiary Baike Bio to the Shanghai Stock Exchange Science and Technology Board listingAfter the completion of this spin-off, Changchun high-tech equity structure will not change and still own a controlling stake in Baike BioThrough this spin-off, Changchun Gaoxin will focus more on genetically engineered drugs, traditional Chinese medicine and real estate business, and Baike Bio will rely on the SSE's science and technology platform to independently finance the development of its own human bio-vaccine research and development, production and sales businessOn the 25th,, Regenerative Yuan announced the start of a public secondary issue of its common stock, and Sanofi will withdraw its investment in Regenerative Yuan shares through the offering planIt is reported that Sanofi currently owns about 23.2 million shares of Renewable Dollar, of which 12.8 million shares are planned for public offering At Monday's closing price of $569.91, Sanofi's shares will be worth more than $7 billion It will be the biggest public offering on record in the healthcare industry (Sina Pharmaceutical News) recently announced the completion of a $100 million C-round financing by ARCH Venture Partners, 8VC and others to expand its company to provide better care for patients with severe mental illness, as part of virtual medical models and digital measurement methods Who World Health Organization Director-General Tan Desai said at a press conference on the 25th, for safety reasons, WHO has suspended the new coronary pneumonia patients in the antimalarial drug hydroxychloroquine clinical trials "The enforcement team has suspended the use of hydroxychloroquine in the 'solidarity test' and the Data Security Monitoring Committee is evaluating the safety data," Tandeser said (Reuters) 26, the State Drug Administration website updated the baiji Shenzhou BTK inhibitor Zebtini processing status, changed to "in approval." It is reported that the corresponding indications of the two acceptance numbers are: recurrent/difficult-treatable set of cell lymphoma, recurrent refractory chronic lymphocytic leukemia/small lymphocytic lymphocytic lymphocytic sympathiser (Sina Pharmaceutical News) China Biopharma announced that its new drug market application for the PD-1 mono-anti-drug Annico (Paampley, AK105), jointly developed by Kangfang Bio, has been accepted by the State Drug Administration for the treatment of recurrent or refractory classic Hodgkin's lymphoma (cHL) patients (Pharmaceutical Rubik's Cube) 26, Stone Pharmaceutical Group submitted the "Oseltaway Capsules" 4 class of generic drugs listed application stomped by CDE Oseltamivir is a specific inhibitor that acts on neuraminidase to inhibit the development of influenza viruses from host cells, thereby inhibiting the spread of influenza viruses in the human body to treat influenza (Insight database) 25, Guizhou Bailing official website announced that a number of test results show that Guizhou Bailing exclusive miao medicine cough fast stop syrup, cough ingestain capsules two drugs to treat the new coronavirus pneumonia (light and common type) is conducive to disease recovery and new coronavirus turn, can shorten the cough time Guizhou Bailing intends to submit an application to CDE to revise the "Drug Specification" of cough-fast-stopping syrup and cough-clearing capsules (Guizhou Bailing official website) Qilu Pharmaceutical is a West Metan tablets through consistency evaluation, for the first in the country Manufacturers of isimetan tablets in the domestic market have Pfizer, Qilu Pharmaceuticals and Zhejiang Pharmaceuticals, but have not yet passed a consistent evaluation (Pharmaceutical Rubik's Cube) 25, East Sunshine declared 3 types of generic drug Esofraazole magnesium intestinal capsule sonatium capsule approved by the State Drug Administration listed, the first through the consistency evaluation (Pharmaceutical Rubik's Cube) Chengdu Baiyu Pharmaceuticals according to the new 4 categories of declared injection of sodium with Paracybu listing application to obtain approval from the State Drug Administration, as if through a consistent evaluation This is the first domestic drug through the consistency evaluation of the manufacturer (Pharmaceutical Rubik's Cube) Cinda Bio announced that it developed a recombinant whole human-based anti-human protein-containing protein-based sequence and immune receptor tyrosine inhibitory base sequence domain of T-cell immunoreceptor (TIGIT) monoclonal antibody (IBI-939) phase I clinical study completed the first patient administration in China (Pharmaceutical Rubik's Cube) recently, NMPA official website shows that Sanofi declared imported therapeutic biological products injection with Laroni enzyme solution listing application, has entered the approval stage, will be approved for listing, become another clinically needed new drug based on the clinical marketable varieties (CPhI PharmaceuticalSOnline) Merck's biopharmaceutical company Merck Sherano recently released long-term efficacy and safety data for oral, highly selective BTK inhibitor evobrutinib for treating adult patients with recurrent multiple sclerosis These results are derived from the Phase II Open Label Extension Study Bayer, the , has submitted a new drug application for its precision oncology drug, Vitrakinib, to Japan's Ministry of Health, Labour and Welfare Vitrakvi is an oral TRK inhibitor specifically designed to treat children and adults with advanced or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusion in tumors (Bio Valley) recently, Novartis second-generation ALK inhibitor Seritini capsule new indications (acceptance number: JXHS1900008) has been changed to "in approval", is expected to be approved for listing in the near future Seretini is the first second-generation ALK inhibitor to enter China, and this indication is predicted to be a first-line treatment of ALK-positive NSCLC (CPhI PharmaceuticalSOnline) MorphoSys and Incyte recently jointly announced that the European Medicines Agency has accepted the marketing authorization application (MAA) of tafasitamab (MOR208), which seeks approval of tafasitamab combined to treat adult patients with recurrent or incurable diffuse large B-cell lymphoma (r/rLB DCL) for treatment of recurrent or incurable diffuse large B-cell lymphoma (r/rLB DCL) patients (Bio Valley) FDA announced recently that it will partner with Aetion, a health technology start-up focused on TheRWE, to launch a new research project focusing on real-world evidence, using data collected by insurance companies, electronic medical records and other medical fields to gain a more in-depth understanding of COVID-19, including the best way to diagnose, use drugs and design-related testing (Pharmaceutical Mingkant)